Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU1-56P (RNA, U1 small nuclear 56, pseudogene) is a human pseudogene belonging to the small nuclear RNA (snRNA) family, specifically annotated as a U1 snRNA pseudogene[1][3]. Genuine U1 small nuclear RNAs are key components of the spliceosome machinery, involved in the recognition of 5’ splice sites and initiation of pre-mRNA splicing. However, as a pseudogene, RNU1-56P is a genomic sequence similar to U1 snRNA genes but is considered non-functional and is not known to produce a functional RNA product or protein[1][3]. There are no established biological functions, disease roles, or drug interactions attributed to this pseudogene. It is not considered a therapeutic target. Key details and rationale: - RNU1-56P is explicitly described as a pseudogene in authoritative gene databases[1][3]. - Small nuclear RNA pseudogenes do not encode proteins and generally do not produce functional RNAs; hence, they are not targets for therapeutic drugs or biomarker applications[1][3][6]. - No literature supports a role for RNU1-56P in disease, therapeutics, or as a biomarker. - The canonical gene for functional U1 snRNA is RNU1-1 (or variants such as RNU1-2); RNU1-56P should not be confused with these functional genes[2][5]. - The molecular classification as a small nuclear RNA pseudogene is based on the nomenclature maintained by HGNC and supporting genomics resources[1][3][6]. - Aliases are limited as the name is unique and standardized in major databases[1][3]. If you need information about the functional U1 small nuclear RNA (not the pseudogene), those molecules have roles in mRNA splicing and are considered important for gene expression regulation[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 56, pseudogene (RNU1-56P).